I agree that this site is using cookies. You can find further informations here.
X
Eckert, Doerthe
25  results:
Search for persons X
?
1

Pharmacokinetics and Exposure–Response Analyses to Support ..:

Bhatnagar, Sumit ; Schlachter, Louisa ; Eckert, Doerthe...
Clinical Pharmacology & Therapeutics.  , 2024
Link: https://doi.org/10.1002/..
 
?
2

Population pharmacokinetics and exposure‐response analyses ..:

Bhatnagar, Sumit ; Eckert, Doerthe ; Stodtmann, Sven...
Clinical and Translational Science.  17 (2024)  2 - p. , 2024
Link: https://doi.org/10.1111/..
 
?
3

Cedirogant Population Pharmacokinetics and Pharmacodynamic ..:

Maier, Corinna S. ; Eckert, Doerthe ; Laroux, F. Stephen...
Clinical Pharmacology in Drug Development.  13 (2024)  5 - p. 474-484 , 2024
Link: https://doi.org/10.1002/..
 
?
4

Venetoclax in biomarker‐selected multiple myeloma patients:..:

Badawi, Mohamed ; Coppola, Sheryl ; Eckert, Doerthe...
Hematological Oncology.  42 (2023)  1 - p. , 2023
Link: https://doi.org/10.1002/..
 
?
5

43131 Population Pharmacokinetic and Pharmacodynamic Analys..:

Maier, Corinna ; Eckert, Doerthe ; Laroux, Stephen...
Journal of the American Academy of Dermatology.  89 (2023)  3 - p. AB75 , 2023
Link: https://doi.org/10.1016/..
 
?
6

Tu1733 UPADACITINIB PHARMACOKINETIC AND EXPOSURE-RESPONSE R..:

Bhatnagar, Sumit ; Schlacter, Louisa ; Eckert, Doerthe...
Gastroenterology.  164 (2023)  6 - p. S-1100-S-1101 , 2023
Link: https://doi.org/10.1016/..
 
?
7

Population pharmacokinetic and exposure‐response modelling ..:

Ismail, Mohamed ; Doelger, Eva ; Eckert, Doerthe...
British Journal of Clinical Pharmacology.  89 (2023)  10 - p. 3139-3151 , 2023
Link: https://doi.org/10.1111/..
 
?
8

Upadacitinib Population Pharmacokinetics and Exposure-Respo..:

Ponce-Bobadilla, Ana Victoria ; Stodtmann, Sven ; Eckert, Doerthe...
Clinical Pharmacokinetics.  62 (2022)  1 - p. 101-112 , 2022
Link: https://doi.org/10.1007/..
 
?
9

Exposure‐Response Model With Time‐Varying Predictors to Est..:

Stodtmann, Sven ; Eckert, Doerthe ; Joshi, Rujuta...
The Journal of Clinical Pharmacology.  62 (2022)  10 - p. 1236-1246 , 2022
Link: https://doi.org/10.1002/..
 
?
10

Venetoclax exposure‐efficacy and exposure‐safety relationsh..:

Brackman, Deanna ; Eckert, Doerthe ; Menon, Rajeev...
Hematological Oncology.  40 (2022)  2 - p. 269-279 , 2022
Link: https://doi.org/10.1002/..
 
?
11

A Population Pharmacokinetic Meta‐Analysis of Veliparib, a ..:

Stodtmann, Sven ; Nuthalapati, Silpa ; Eckert, Doerthe...
The Journal of Clinical Pharmacology.  61 (2021)  9 - p. 1195-1205 , 2021
Link: https://doi.org/10.1002/..
 
?
12

Pharmacokinetics of Risankizumab in Asian Healthy Subjects ..:

Khatri, Amit ; Eckert, Doerthe ; Oberoi, Rajneet...
The Journal of Clinical Pharmacology.  59 (2019)  12 - p. 1656-1668 , 2019
Link: https://doi.org/10.1002/..
 
?
13

Population Pharmacokinetics of Glecaprevir/Pibrentasvir in ..:

Suleiman, Ahmed Abbas ; Lin, Chih‐Wei ; Liu, Wei...
The Journal of Clinical Pharmacology.  60 (2019)  3 - p. 331-339 , 2019
Link: https://doi.org/10.1002/..
 
?
14

Impact of Venetoclax Exposure on Clinical Efficacy and Safe..:

Freise, Kevin J. ; Jones, Aksana K. ; Eckert, Doerthe...
Clinical Pharmacokinetics.  56 (2016)  5 - p. 515-523 , 2016
Link: https://doi.org/10.1007/..
 
?
15

Population pharmacokinetics of paritaprevir, ombitasvir, da..:

Mensing, Sven ; Eckert, Doerthe ; Sharma, Shringi...
British Journal of Clinical Pharmacology.  83 (2016)  3 - p. 527-539 , 2016
Link: https://doi.org/10.1111/..
 
1-15